Article Information
History
- February 14, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Chandrav Dea,
- Dongmei Liub,
- Daniel Depledgec,
- Judith Breuerc,
- Uma S. Singhe,
- Caroll Hartlined,
- Mark N. Prichardd,
- Chung K. Chue and
- Jennifer F. Moffatb,*
- aDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
- bDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse NY, USA
- cMRC/UCL Centre for Medical Molecular Virology, Division of Infection & Immunity, University College London, UK
- dDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA
- eDepartment of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens GA, USA
- ↵*Corresponding Author
Jennifer F. Moffat, PhD, Department of Microbiology and Immunology SUNY Upstate Medical University, 750 East Adams Street, Syracuse NY, 13210, Telephone: 315-464-5454, moffatj{at}upstate.edu
Posted February 14, 2020.
β-L-1-[5-(E-2-Bromovinyl)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)] uracil (L-BHDU) effectiveness against varicella-zoster virus and herpes simplex virus type 1 depends on thymidine kinase activity
